^
BIOMARKER:

PD-L1 negative

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
PD-L1 negative
Cervical Cancer
pembrolizumab + tirvalimogene teraplasmid
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
TPeX
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive
:
A2
PD-L1 negative
Melanoma
pembrolizumab
Sensitive
:
B
PD-L1 negative
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
C2
PD-L1 negative
Non Small Cell Lung Cancer
avelumab + VX15
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
nivolumab
Resistant
:
C3
PD-L1 negative
Urothelial Cancer
nivolumab + IPI-549
Sensitive
:
C3
PD-L1 negative
Vulvar Cancer
pembrolizumab
Sensitive
:
C3
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive
:
C3
PD-L1 negative
Cervical Cancer
AGEN2034
Sensitive
:
C3
PD-L1 negative
Head and Neck Cancer
ABBV-181
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
ABBV-181
Sensitive
:
C3
PD-L1 negative
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
C3
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + SNS-301
Sensitive
:
C4
PD-L1 negative
Merkel Cell Carcinoma
avelumab
Sensitive
:
C4
PD-L1 negative
Small Cell Lung Cancer
pembrolizumab
Sensitive
:
C4
PD-L1 negative
Small Cell Lung Cancer
anlotinib + camrelizumab
Sensitive
:
C4
PD-L1 negative
Colon Cancer
SAR445710
Sensitive
:
D